Plasma drug-concentrations in patients with pulmonary arterial hypertension on combination treatment
E Grünig, J Ohnesorge, N Benjamin, J Burhenne, J Song, B Egenlauf, C Fischer, S Harutyunova, A Huppertz, H Klose, WE Haefeli · Pneumologie · 2016 · Heft 07
Bibliografische Angaben
Zusammenfassung
Introduction: Combination therapy of the phosphodiesterase-type 5 inhibitors (PDE-5i) sildenafil or tadalafil and endothelin receptor antagonists bosentan, ambrisentan, or macitentan may cause mutual pharmacokinetic interactions in patients with pulmonary arterial hypertension (PAH). The objective of this study was to analyse plasma drug concentrations in PAH-patients during different combination treatments. Methods: PAH patients receiving a stable combination treatment with ERA and PDE-5i with targeted dosage for at least one month were routinely assessed, including clinical parameters and plasma drug concentra…
